Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Teleflex - Caught on Camera

Recalled Newborn Breathing Circuits Land in the FDA's Middle Risk Tier After Reports of Connectors Melting

The FDA classified the Medline neonatal breathing circuit recall as Class II. What the middle risk tier means for families with an infant on a ventilator.

Medical Daily

Neonatal Breathing Circuits Recalled After Melting and Smoke Reports, with Two Item Numbering Systems Confusing Hospitals

The FDA issued an early alert after neonatal breathing circuits were found to be melting and emitting smoke. Medline wants all affected lots destroyed.

Medical Daily

FDA Licenses the First Freeze Dried Plasma Product for U.S. Adults When Frozen Plasma Is Not Available

The FDA licensed Ezplaz Freeze-Dried Plasma, the first shelf-stable plasma product cleared in the U.S. for adults experiencing bleeding when frozen plasma is unavailable.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Licenses First Freeze-Dried Plasma for U.S. Adults When Frozen Plasma Is Not Available

FDA-licensed Ezplaz is the first freeze-dried plasma in the US. It is approved as a backup when frozen plasma is unavailable, not a replacement.

Medical Daily

FDA Licenses the First Freeze Dried Plasma for Use in the United States

FDA licensed Ezplaz, the first freeze-dried plasma in the US, for adults needing plasma when other plasma products are not available.

Medical Daily

Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

MarketBeat

How Is Teleflex’s Stock Performance Compared to Other Medical Instruments & Supplies Stocks?

Due to Teleflex’s underperformance relative to its industry peers over the past six months, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Teleflex Stock: Analyst Estimates & Ratings

Teleflex has continued to underperform the broader market over the past several years, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Here's What to Expect From Teleflex's Next Earnings Report

Teleflex is poised to post its fourth-quarter earnings by the end of next month, and analysts are expecting a modest-double-digit rise in its earnings.

Barchart

Teleflex Stock: Is TFX Underperforming the Healthcare Sector?

Although Teleflex has underperformed relative to the healthcare sector over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Do Wall Street Analysts Like Teleflex Stock?

Despite Teleflex’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Teleflex's Report

Teleflex is set to report its third-quarter earnings by the end of this month, with analysts projecting a slight decline in its bottom line.

Barchart

Is Teleflex Stock Underperforming the Dow?

Despite Teleflex’s underperformance relative to the Dow Jones over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Teleflex Stock Outlook: Is Wall Street Bullish or Bearish?

Although Teleflex has lagged behind the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Tribune News Service

Medtronic weighs appeal after losing patent case regarding catheter technology

MINNEAPOLIS — Medtronic is weighing its next steps after losing another round in a long-running patent dispute with med-tech competitor Teleflex Inc.

Benzinga

RBC Capital Sees Meaningful M&A Execution For This Critical Care-Focused Stock

Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF.

Benzinga

Expert Ratings for Teleflex

Over the past 3 months, 12 analysts have published their opinion on Teleflex (NYSE:TFX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

StockNews.com

Scoop Up These 4 Buy-Rated Healthcare Stocks Trading Near 52-Week Lows

Despite the prevailing bearish investor sentiment, the healthcare industry is expected to continue growing amid an increase in global chronic diseases, rapid medical advancements, and an aging population. The stocks of quality healthcare companies Bausch Health (BHC), Teleflex (TFX), Abcam (ABCM), and Integra LifeSciences (IART) are currently trading near their…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Upgrades

Benzinga

Looking Into Teleflex's Return On Invested Capital

According to Benzinga Pro, during Q1, Teleflex (NYSE:TFX) earned $77.14 million, a 39.77% increase from the preceding quarter. Teleflex's sales decreased to $641.72 million, a 15.78% change since Q4.

Benzinga

Why These Analysts Cut Price Target On Teleflex

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance.

Benzinga

Needham Maintains Buy Rating for Teleflex: Here's What You Need To Know

Needham has decided to maintain its Buy rating of Teleflex (NYSE:TFX) and lower its price target from $400.00 to $355.00. Shares of Teleflex are trading down 1.62% over the last 24 hours, at $290.71 per share. A move to $355.00 would account for a 22.11% increase from the current share…

Benzinga

Expert Ratings for Teleflex

Over the past 3 months, 7 analysts have published their opinion on Teleflex (NYSE:TFX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Teleflex: Q1 Earnings Insights

Teleflex (NYSE:TFX) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

How To Attend Teleflex Q1 2022 Earnings Conference Call

Teleflex (NYSE:TFX) will host a conference call at 08:00 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.

1 2

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

blockchain

1,649 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.